Events - Pharvaris N.V.

Past Events

Jun 9 - Jun 11, 2023

European Academy of Allergy & Clinical Immunology (EAACI) Congress 2023

Supporting Materials

Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

Treatment with Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 Improves Hereditary Angioedema Attack Symptoms 1.1 MB

Efficacy and Safety of Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe-1 Phase 2 Trial 700.6 KB

May 4 - May 7, 2023

13th C1-inhibitor Deficiency and Angioedema Workshop

Supporting Materials

Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop

The EC85 Derived from the Oral Bradykinin B2 Receptor Antagonist Deucrictibant (PHA121) Against Bradykinin Effects in Healthy Volunteers Predicts the Onset and Duration of Its Clinical Effects in Hereditary Angioedema 1.1 MB

Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate Release Capsule (PHVS416) in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe 1 Phase 2 Trial 870.7 KB

Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks 850.4 KB

Cardiovascular safety of the orally administered bradykinin B2 receptor antagonist, deucrictibant (PHA121, PHA-022121) 1.1 MB

Efficacy of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) by attack location in the RAPIDe-1 phase 2 clinical trial for treatment of hereditary angioedema attacks 1.6 MB

Mar 18, 2023 11:35 AM +07

2023 HAEi Regional Conference APAC

Supporting Materials

Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial 920.2 KB

Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

Feb 26, 2023 9:45 AM CST

AAAAI Annual Meeting 2023

Supporting Materials

Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial 1.1 MB

Dr. Marcus Maurer Audio Session (MP4) 6.3 MB

Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting

Dec 8, 2022 8:00 AM EST

RAPIDe-1 Phase 2 Top-line Data

Supporting Materials

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks 193.1 KB

RAPIDe-1 Phase 2 Top-line Data Presentation 2.2 MB

Click for Webcast 19.5 MB

Nov 10 - Nov 14, 2022

ACAAI Annual Scientific Meeting 2022

Supporting Materials

Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022

Development of PHVS719: an Oral Extended-Release Bradykinin B2 Receptor Antagonist to Prevent Hereditary Angioedema Attacks 818.4 KB

Pharmacokinetics of PHVS719, extended-release tablet formulation of PHA121, a first-in-class oral human bradykinin B2-receptor antagonist 937.4 KB

Oct 7, 2022 2:30 PM CEST

2022 HAEi Global Leadership Workshop

Supporting Materials

Development of two novel oral formulations of a first in class bradykinin B2 receptor antagonist for on demand and prophylactic treatment of hereditary angioedema 920.1 KB

Sep 16, 2022 10:45 AM CEST

2022 Bradykinin Symposium

Supporting Materials

Development of PHA121 for On-Demand and Prophylactic Treatment of HAE 926.6 KB

Jun 29, 2022 10:00 AM EDT

2022 Annual General Meeting of Shareholders

Supporting Materials

Annual Report and Auditor’s Report 2021 3.6 MB

Convening Notice and Agenda 1.1 MB

AGM Announcement 16.9 KB

Voting Proxy 251.6 KB

Jun 5 - Jun 8, 2022

Kinin2022 Conference

Supporting Materials

Pharvaris Kinin 2022 1.6 MB

Pharvaris Participates in the Kinin 2022 Conference

Pagination

First page
Previous page
…
Page 7
Page 8
Current page 9
Page 10
Next page
Last page

Presentations

Source:

EAACI Annual Congress 2026, Istanbul, Turkey

Clinical Cardiovascular Safety Assessment of Oral Deucrictibant

Source:

EAACI Annual Congress 2026, Istanbul, Turkey

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial

Source:

EAACI Annual Congress 2026, Istanbul, Turkey

A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema

Latest Corporate Presentation